Invest in Cancer Treatment with Tocagen
On our last investment tip in CRISPR
technologies, we are evaluating Tocagen. Tocagen is a company involved in
genetic therapies aiming to develop cancer treatments. The company has three
drug candidates in development, one of which is a treatment for recurrent
high-grade glioma, this drug is at the critical Phase 3 of development.
Tocagen finished last year with sharing
with its investors the companys addition to the NASDAQ Biotechnology Index
(NASDAQ: NBI), this is one of the leading exchange-traded funds (ETFs) in the
industry. Also in Q4 and the financial results of 2017, the company announced
promising development on two drugs under development. Toca 6 reported activity
and safety data and complete enrolment for the Phase 3 testing. Also, Toca 5 is
advancing in its trial stages.
Events to watch
In April, Tocagen will present
preliminary Phase 1 data from the Toca 6 trial at the American Association of
Cancer Research meeting. The company has also received orphan medical
designation for previous drugs; Toca 511 and Toca FC to treat glioma by the
European Medicines Agency.
Currently,
Tocagen (NASDAQ: TOCA) is trading at $10,98 with a market capitalization of
$219,7 million. The stock has seen a steady decline since the IPO last year,
however, we are expecting better performances from Tocagen as new and
interesting drugs hit the market.
Comments
Post a Comment